203 related articles for article (PubMed ID: 30822182)
41. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
42. An observation study of the clinical evaluation of symptom relief and side effects associated with taking ulipristal acetate (esmya) including its effect on pre-menstrual syndrome.
Chen BF; Powell MC; O'Beirne C
J Obstet Gynaecol; 2017 Jul; 37(5):645-648. PubMed ID: 28498002
[TBL] [Abstract][Full Text] [Related]
43. Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids.
Syed YY
Drugs; 2022 Oct; 82(15):1549-1556. PubMed ID: 36331779
[TBL] [Abstract][Full Text] [Related]
44. Ulipristal acetate prior to in vitro fertilization in a female patient affected by uterine fibroids: a case report.
Lo Monte G; Piva I; Graziano A; Engl B; Marci R
Eur Rev Med Pharmacol Sci; 2016; 20(2):202-7. PubMed ID: 26875885
[TBL] [Abstract][Full Text] [Related]
45. Phase III long-term study to evaluate the efficacy and safety of ulipristal acetate in Japanese patients with uterine fibroids.
Osuga Y; Nakano Y; Yamauchi Y; Murakawa H
J Obstet Gynaecol Res; 2021 Sep; 47(9):3269-3278. PubMed ID: 34109697
[TBL] [Abstract][Full Text] [Related]
46. The potential role of elagolix for treating uterine bleeding associated to uterine myomas.
Barra F; Vitale SG; Seca M; Scala C; Leone Roberti Maggiore U; Cianci A; Ferrero S
Expert Opin Pharmacother; 2020 Aug; 21(12):1419-1430. PubMed ID: 32401547
[TBL] [Abstract][Full Text] [Related]
47. Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas.
Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; McKain L; Li Y; Wagman RB; Stewart EA
Obstet Gynecol; 2022 Dec; 140(6):920-930. PubMed ID: 36357960
[TBL] [Abstract][Full Text] [Related]
48. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.
Archer DF; Stewart EA; Jain RI; Feldman RA; Lukes AS; North JD; Soliman AM; Gao J; Ng JW; Chwalisz K
Fertil Steril; 2017 Jul; 108(1):152-160.e4. PubMed ID: 28579415
[TBL] [Abstract][Full Text] [Related]
49. The history and use of the progesterone receptor modulator ulipristal acetate for heavy menstrual bleeding with uterine fibroids.
Bouchard P; Chabbert-Buffet N
Best Pract Res Clin Obstet Gynaecol; 2017 Apr; 40():105-110. PubMed ID: 28169130
[TBL] [Abstract][Full Text] [Related]
50. Ulipristal acetate and liver-injuries: while Esmya is revoked, EllaOne is allowed in repeated self-administrations possibly exceeding UPA toxic-dosing with Esmya.
Mozzanega B
J Hepatol; 2021 Mar; 74(3):750-751. PubMed ID: 33271158
[No Abstract] [Full Text] [Related]
51. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.
Ferrero S; Vellone VG; Barra F
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):107-116. PubMed ID: 29250979
[TBL] [Abstract][Full Text] [Related]
52. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.
Tafi E; Scala C; Leone Roberti Maggiore U; Bizzarri N; Candiani M; Venturini PL; Ferrero S
Expert Opin Drug Saf; 2015 Jun; 14(6):965-77. PubMed ID: 25772793
[TBL] [Abstract][Full Text] [Related]
53. The medical management of abnormal uterine bleeding in reproductive-aged women.
Bradley LD; Gueye NA
Am J Obstet Gynecol; 2016 Jan; 214(1):31-44. PubMed ID: 26254516
[TBL] [Abstract][Full Text] [Related]
54. The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids.
Pohl O; Zobrist RH; Gotteland JP
Reprod Sci; 2015 Apr; 22(4):476-83. PubMed ID: 25228633
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of ulipristal acetate in women with fibroid induced menorrhagia: A systematic review and meta-analysis.
Kounidas G; Kastora SL; Barnott E; Black L; Robinson-Burke T; Gould A; Morgan D; Urquhart G; Poobalan A; Jack A
J Gynecol Obstet Hum Reprod; 2021 Nov; 50(9):102173. PubMed ID: 34082168
[TBL] [Abstract][Full Text] [Related]
56. Oriahnn: New Drug Approved for Treating Heavy Menstrual Bleeding in Women With Uterine Fibroids.
Lynch SE; Mayer DC
Ann Pharmacother; 2022 Jan; 56(1):93-101. PubMed ID: 33998300
[TBL] [Abstract][Full Text] [Related]
57. Gene expression changes in uterine myomas in response to ulipristal acetate treatment.
Courtoy GE; Donnez J; Ambroise J; Arriagada P; Luyckx M; Marbaix E; Dolmans MM
Reprod Biomed Online; 2018 Aug; 37(2):224-233. PubMed ID: 29807764
[TBL] [Abstract][Full Text] [Related]
58. Ulipristal acetate in symptomatic uterine fibroids. A real-world experience in a multicentric Italian study.
Giarrè G; Franchini M; Castellacci E; Malune ME; Di Spiezio Sardo A; Saccone G; Angioni S
Gynecol Endocrinol; 2020 Feb; 36(2):171-174. PubMed ID: 31392917
[TBL] [Abstract][Full Text] [Related]
59. Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate.
Yun BS; Seong SJ; Jung YW; Kim ML; Bae HS; Kim MK; Shim SS
Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():133-136. PubMed ID: 29602142
[TBL] [Abstract][Full Text] [Related]
60. Ulipristal Acetate Before High Complexity Hysteroscopic Myomectomy: A Retrospective Comparative Study.
Ferrero S; Racca A; Tafi E; Alessandri F; Venturini PL; Leone Roberti Maggiore U
J Minim Invasive Gynecol; 2016; 23(3):390-5. PubMed ID: 26707918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
